A phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma following prior high dose chemotherapy and autologous stem cell rescue

• Register: ISRCTN
• Last refreshed on: 7 November 2022
• Main ID: ISRCTN60123120
• Date of registration: 26/01/2007
• Prospective Registration: Yes
• Primary sponsor: The Leeds Teaching Hospitals NHS Trust (UK)
• Public title: A phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma following prior high dose chemotherapy and autologous stem cell rescue
• Scientific title: A phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma following prior high dose chemotherapy and autologous stem cell rescue
• Date of first enrolment: 01/09/2007
• Target sample size: 320
• Recruitment status: Completed
• URL: https://www.isrctn.com/ISRCTN60123120
• Study type: Interventional
• Study design: Randomised, multicentre, open labelled, parallel group phase III trial (with single intervention registration phase). (Treatment)
• Phase: Phase III

Countries of recruitment

England, United Kingdom

Contacts

• Name: Suzanne Hartley

Key inclusion & exclusion criteria

Inclusion criteria:
Inclusion criteria amended as of 24/08/2007:

Registration:
1. Diagnosed with symptomatic (including non-secretory) Multiple Myeloma (MM) previously treated with standard chemotherapy and autologous transplantation
2. Requiring therapy for first Progressive Disease (PD) (where PD is determined according to the International uniform response criteria for myeloma. Patients previously immunofixation negative who are now immunofixation positive need to demonstrate a greater than 5 g/liter absolute increase in paraprotein to be eligible for inclusion)
3. Demonstrate PD requiring treatment at least 18 months from time of first transplant
4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
5. Aged at least 18 years
6. Adequate full blood count within 14 days before registration:
a. Platelet count greater than or equal to 50 x 109/L
b. Absolute Neutrophil Count (ANC) greater than or equal to 1 x 109/L
7. Adequate renal function within 14 days before registration:
a. Creatinine clearance greater than or equal to 30 ml/min
8. Adequate hepatobiliary function within 14 days before registration:
a. Total bilirubin less than 2 x Upper Limit of Normal (ULN)
b. ALanine aminoTransferase (ALT) or ASpartate aminoTransferase (AST) less than 2.5 x ULN
9. Adequate pulmonary function within 14 days before registration:
a. No evidence of a history of pulmonary disease. If a history, then KCO/DLCO (Carbon Monoxide diffusion in the lung) greater than or equal to 50% and/or no requirement for supplementary continuous oxygen
10. Adequate cardiac function within 14 days before registration:
a. Left Ventricular Ejection Fraction (LVEF) greater than or equal to 40% by ElectroCardioGram (ECG) or Multiple Gated Acquisition (MUGA) scan
11. If female and of childbearing potential, must have a negative pregnancy test (either serum or urine Human Choronic Gonadotropin [HCG]) within 24 hours prior to start of PAD therapy
12. Provided written informed consent

Randomisation:
1. Registered into the Myeloma X Relapse (Intensive) trial and received 2-4 cycles of PAD re-induction chemotherapy according to the protocol
2. Responded ([s]Complete Response [CR] or [VG] Partial Response [PR]) or have Stable Disease (SD), following PAD re-induction chemotherapy according to the International Uniform Response Criteria for myeloma
3. Adequate stem cell mobilisation defined as greater than or equal to 2 x 106 CD34+ cells/kg or greater than or equal to 2 x 108 Peripheral Blood Mononuclear Cells (PBMC)/kg available for transplantation (including cells stored from a previous harvest)
4. Adequate full blood count within 14 days before randomisation:
a. Platelet count greater than or equal to 50 x 109/L
b. ANC greater than or equal to 1 x 109/L
5. Adequate renal function within 14 days before randomisation:
a. Creatinine clearance greater than or equal to 30 ml/min
6. Adequate hepatobiliary function within 14 days before randomisation:
a. Total bilirubin less than 2 x ULN

Exclusion criteria:
Exclusion criteria amended as of 24/08/2007:

Registration:
1. Received therapy for their relapsed disease other than local radiotherapy, therapeutic plasma exchange, or dexamethasone up to a maximum of 200 mg. (Radiotherapy since pervious transplant sufficient to alleviate or control pain of local invasion is permitted. Patients who have received hemi-body radiation or similar since previous transplant will not be eligible)
2. ECOG Performance Status 3-4
3. Greater than or equal to Grade 2 peripheral neuropathy within 14 days before registration
4. Known HIV or Hepatitis B/C seropositivity (testing is not required for the trial)
5. Use of any investigational drug within 4 weeks prior to registration, or scheduled to receive any investigational drug during the course of the study
6. Known resistance to combined bortezomib, doxorubicin and dexamethasone (PAD) therapy
7. Known history of allergy contributable to compounds containing boron or mannitol
8. Any medical or psychiatric condition which, in the opinion of the investigator, contraindicates the patient's participation in this study
9. Previous or concurrent malignancies at other sites, with the exception of appropriately treated localised epithelial skin or cervical cancer. Patients with remote histories (>5 years) of other cured tumours may be entered
10. Pregnant or breast feeding
11. Unwilling to use adequate contraception during the study and for 6 months after the end of the study treatment if female of childbearing potential, or male whose partner is a female of childbearing potential unless they are surgically sterile

Randomisation:
1. Received any therapy for their relapsed disease, other than local radiotherapy or protocol PAD treatment, prior to randomisation. (Radiotherapy sufficient to alleviate or control pain of local invasion is permitted. Patients who have received hemi-body radiation or similar since previous transplant will not be eligible)
2. Progressive disease, according to International Uniform Response Criteria for myeloma following PAD re-induction therapy or stem cell mobilisation
3. Any contra-indication to protocol treatment that would make the patient ineligible

Exclusion criteria provided at time of registration:

Registration:
1. Patients who have received therapy for their relapsed disease other than local radiotherapy, therapeutic plasma exchange or dexamethasone up to a maximum of 200 mg
2. Females of child-bearing potential without a negative pregnancy test, immediately prior to the start of PAD therapy and/or unwilling to use barrier contraceptive precautions throughout the study or who are pregnant or breast-feeding
3. Non-secretory MM
4. Performance status three to four (ECOG)
5. Platelet count less than 50 x 10^9/L within 14 days before enrolment
6. Absolute neutrophil count less than 1.0 x 10^9/L within 14 days before enrolment
7. Grade two peripheral neuropathy within 14 days before enrolment
8. Presence of severe irreversible renal, hepatic, pulmonary or cardiac disease such as:
a. Total bilirubin,

Age minimum:
Age maximum:
Gender: Both

Health Condition(s) or Problem(s) studied

Relapsed Multiple Myeloma
Cancer
Myeloma

Intervention(s)

Interventions amended as of 24/08/2007:

All registered patients will receive 2 to 4 x 21 day cycles of PAD (bortezomib, doxorubicin and dexamethasone):

Bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 of each cycle via intravenous bolus
Doxorubicin 9 mg/ m2 on days 1 to 4 of each cycle via continuous intravenous infusion
Dexamethasone 40 mg/day on days 1 to 4, 8 to 11, 15 to 18 for cycle 1 and days 1 to 4 for cycles 2 to 4, orally

Patients who undergo Peripheral Blood Stem Cell (PBSC) mobilisation and harvest will receive:

Cyclophosphamide 1.5 to 3 mg/m2 on day 0 via intravenous infusion
Granulocyte-Colony-Stimulating Factor (G-CSF) 5-10 microgram/kg/day from day 1 to time of harvest via subcutaneous

Patients who undergo randomisation will be allocated to receive:

High-dose melphalan 200 mg/m2 on day 0 via intravenous infusion

OR

Low dose cyclophosphamide 400 mg/m2 weekly for 12 weeks, orally

Interventions provided at time of registration:

Registration:
All patients will receive two to four cycles of PAD (bortezomib, dexamethasone and adriamycin).

Peripheral Blood Stem Cell (PBSC) mobilisation:
Stem cells will be mobilised using cyclophosphamide, if stored cells are available from a previous harvest, omission of this mobilisation step is permitted.

Randomisation:
Patients who meet the eligibility for randomisation will receive consolidation therapy with either:
1. High-dose melphalan therapy supported by re-infusion of autologous stem cells;

Primary Outcome(s)

Primary outcome measures amended as of 24/08/2007:

Primary outcome measure is time to disease progression and is defined as time from randomisation to the consolidation part of the trial to first documented evidence of disease progression. Patients who die prior to documentation of disease progression will be censored in the analysis. Central analysis of blood and urine samples (and bone marrow if needed) will by monitored at regular internals (at least post-reinduction treatment, 100 days post autologous stem cell transplant/30 days post-end of cyclophosphamide weekly, annually thereafter and if clinically indicated) to assess response/progression. Disease progression and response rates will be determined according to the International Uniform Response Criteria for multiple myeloma.

Primary outcome measures provided at time of registration:

Time to disease progression

Secondary Outcome(s)

Secondary outcome measures amended as of 24/08/2007:

1. Response to PAD re-induction treatment will be determined according to the International uniform response criteria for multiple myeloma through central analysis of blood, urine and bone marrow aspirate (if complete response is indicated from local results).

2. Progression-free survival is defined as the time from randomisation to the consolidation part of the trial to first documented evidence of disease progression or death from any cause. Patients who do not progress will be censored at the last date they were known to be alive and progression free.

3. Overall survival is defined as the time from randomisation to the consolidation part of the trial to death from any cause or last follow-up.

4. The feasibility of stem cell collection will be determined by the satisfactory mobilisation of an adequate number of peripheral blood stem cells (greater than 10 CD34+ cells/µl blood) and the subsequent harvest of sufficient numbers of stem cells to support high-dose chemotherapy (greater than 2.0 x 109 CD34+ cells/kg).

5. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-C30) and EORTC-myeloma module (EORTC QLQ-MY20), the Leeds Assessment of Neuropathic Symptoms and Signs: Self-complete (LANSS) pain scale and the Brief Pain Inventory (short form) will be used to measure patient-assessed Quality of Life (QoL) and evaluate pain in detail. Questionnaires will be administered at baseline, post re-induction treatment, pre-randomisation (if greater than two weeks since the completion of questionnaires post re-induction treatment), 100 days post-randomisation, 6 months post-randomisation, 1 year post-randomisation and annually thereafter.

6. Toxicity and safety will be reported based on adverse events, as graded by Common Terminology Criteria for Adverse Events (CTCAE V3.0) and determined by routine clinical assessments at each centre. This will be assessed throughout the trial.

Secondary outcome measures provided at time of registration:

1. Response rate to PAD
2. Overall response rate following randomised treatments
3. Overall survival
4. Feasibility of stem cell collection
5. Quality of Life (QoL)
6. Toxicity and safety

Secondary ID(s)

HM05/7287

NCT00747877

2006-005890-24

Source(s) of Monetary Support

Cancer Research UK (UK), Chugai Pharma UK (UK) (unrestricted educational grant)

Ethics review

Status:
Approval date:
Contact:

Added 24/08/2007: West Glasgow Ethics Committee 1on 03/07/2007 (ref: 07/S0703/66)

Results

• Results available: Yes
• Date Completed: 30/11/2016